Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7512.074 | 0.0648 | -0.9037 | 0.9022 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7512.074 | 0.0648 | -0.9037 | 0.9022 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 167 | uM | 7512.074 | 0.0545 | -0.9205 | 0.9022 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 167 | uM | 7512.074 | 0.0545 | -0.9205 | 0.9022 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 14845.203 | 1.0171 | 1.0489 | 0.7023 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 14845.203 | 1.0171 | 1.0489 | 0.7023 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 14845.203 | 0.9700 | 0.9152 | 0.7023 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 14845.203 | 0.9700 | 0.9152 | 0.7023 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 14845.203 | 1.0092 | 1.0262 | 0.7023 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 14845.203 | 1.0092 | 1.0262 | 0.7023 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 14845.203 | 0.7882 | 0.4252 | 0.7023 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 14845.203 | 0.7882 | 0.4252 | 0.7023 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 14845.203 | 0.4550 | -0.3483 | 0.7023 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 14845.203 | 0.4550 | -0.3483 | 0.7023 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 14845.203 | 0.2590 | -0.7079 | 0.7023 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 14845.203 | 0.2590 | -0.7079 | 0.7023 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14845.203 | 0.1956 | -0.8042 | 0.7023 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14845.203 | 0.1956 | -0.8042 | 0.7023 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14845.203 | 0.0868 | -0.9384 | 0.7023 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14845.203 | 0.0868 | -0.9384 | 0.7023 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14845.203 | 0.0698 | -0.9548 | 0.7023 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14845.203 | 0.0698 | -0.9548 | 0.7023 | |
| MDA-MB-453 | TNBC | Luminal | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7517.074 | 0.9344 | 0.9134 | 1.5337 | |
| MDA-MB-453 | TNBC | Luminal | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7517.074 | 0.9344 | 0.9134 | 1.5337 | |
| MDA-MB-453 | TNBC | Luminal | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7517.074 | 0.9296 | 0.9070 | 1.5337 |